28 January 2014
EMA/11130/2014
Press Office

Organisational matters

CHMP meeting 20-23 January 2014

The CHMP noted that Aikaterini Moraiti would be leaving her role as Greek CHMP member at the end of this meeting. The Committee thanked her for her contributions and work.

The main organisational topics addressed during the January meeting related to:

- Discussion on the expertise of co-opted CHMP members in the Committee in light of Dr Robert Hemmings' mandate coming to an end in February 2014. The Committee agreed to keep the expertise of co-opted members as is.
- Initial discussion on the proposal for a framework to incorporate patients' views during evaluation of benefit-risk by EMA Scientific Committees. Follow-up discussion will take place over the next few months.
- Follow-on discussion on a reflection paper on the application for similarity assessment for orphan medicinal products. Further discussion is expected next month.
- Discussion on follow-up actions and tasks to be taken forward following the CHMP informal meeting that took place in Vilnius (Lithuania) in October 2013. These related to improved collaboration between the PRAC and CHMP especially on Risk Management Plans assessments, quality of assessment reports, defining criteria for triggering revision of guidelines, strengthening ad-hoc expert groups by developing standardised information package to attendees and piloting a new approach to chairing such meetings and finally networking of multinational assessment teams.
- Update on the Benefit-Risk project and the Phase II pilot phase.
- Follow-up discussion on the wording of indications for medicinal products for treatment of type 2 diabetes.
- Decision to cease activities of the Urology Drafting Group for the time being.
- Endorsement of the Rheumatology-Immunology Working Party response to the CMDh letter regarding interpretation of the Guideline on Clinical Investigation of Medical Products Used in the Treatment of Osteoarthritis. This letter is being forwarded to the CMDh.
- An update from the CHMP sub-group working on supply shortages with reference to development of EMA guidance to support medicines regulators involved in the EU-level coordination of shortage situations due to GMP non-compliance/quality defects which are now published here.

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8409
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

- Information on the move of the EMA to Churchill Place in July 2014.